EQS-News: Marinomed Biotech AG / Key word(s): Study results
Marinomed Biotech AG publishes remarkable results showing alleviation of
allergic eye inflammation in patients treated with Tacrolimus eye drops in
peer-reviewed journal
08.10.2024 / 07:45 CET/CEST
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
Marinomed Biotech AG publishes remarkable results showing alleviation of
allergic eye inflammation in patients treated with Tacrolimus eye drops in
peer-reviewed journal
• Tacrosolv eye drops, a low-dose, aqueous Marinosolv-enabled
formulation of Tacrolimus, are safe and effective in alleviating
symptoms of allergic rhinoconjunctivitis
• Data from phase II dose-finding clinical trial have been published in
peer-reviewed Clinical Ophthalmology journal
• Tacrosolv offers great potential in treatment of inflammatory diseases
of the ocular surface
Korneuburg, Austria, 08. October 2024 – Marinomed Biotech AG (VSE:MARI)
has published clinical data from the phase II dose-finding clinical trial
evaluating the efficacy of Tacrosolv eye drops in patients with allergic
rhinoconjunctivitis in the peer-reviewed “(1)Clinical Ophthalmology”
journal. The placebo-controlled allergen challenge trial assessed the
efficacy and safety of two different doses of Tacrosolv. The results show
that the higher dose of Tacrosolv eye drops (0.005% Tacrolimus)
significantly reduced ocular symptoms of allergic conjunctivitis, and
surprisingly, also the associated nasal allergy symptoms. Remarkably,
these results were achieved with a dose that is 20-fold lower than that of
the only Tacrolimus eye drop product currently on the market.
Eva Prieschl-Grassauer, CSO of Marinomed, comments: “Tacrolimus is an
immunosuppressive compound widely used to prevent organ rejection after
transplantation or for treating inflammatory skin and eye diseases. In
ophthalmology, there is currently only one marketed product in Asia in
which Tacrolimus is used as a suspension. Due to its very low solubility
in water and the associated very low bioavailability in the inflamed
tissue, it takes days to weeks for the therapy to take effect. With our
Marinosolv solubilization technology, we could significantly increase the
solubility of Tacrolimus in a water-based formulation, thereby improving
bioavailability, lowering the needed dose, and leading to a faster onset
of action. The encouraging results of this clinical study show that
Tacrosolv is a safe and effective treatment option for ocular
inflammation. Tacrosolv has the potential to benefit a multitude of
inflammatory eye diseases, where the currently limited treatment options
create unmet medical need.”
In the clinical trial, adults with a history of allergic conjunctivitis
were randomized to either Tacrolimus or placebo treatment for 8 days.
Allergic symptoms were induced by controlled allergen exposure on day 1
and 8. During exposure, participants recorded ocular, nasal and
respiratory allergy symptoms. The primary endpoint was the mean Total
Ocular Symptom Score (TOSS) on day 8. Objective ocular safety parameters
were assessed before, during and after exposure.
On day 8, ocular symptoms (mainly redness and watery eyes) were reduced in
participants receiving Tacrosolv compared to placebo treatment.
Surprisingly, nasal symptoms (mainly itching and sneezing) were
significantly reduced in participants treated with Tacrosolv already after
the first application. This is an outstanding finding, as the only
currently marketed eye drop formulation (Talymus® ophthalmic suspension
0.1%, marketed in Asia) contains a 20-fold higher concentration of
Tacrolimus. In conclusion, treatment with Tacrosolv at the dose and
frequency studied is safe and significantly alleviates symptoms in
participants suffering from allergic rhinoconjunctivitis.
About Marinosolv®:
Marinosolv® is an innovative technology platform that enables the
solubilization and enhances the bioavailability of small molecules and
peptides that are hardly soluble in aqueous formulations. Consequently,
new treatments of a multitude of diseases can be envisaged. The use of the
Marinosolv® technology can facilitate efficient drug delivery with a low
systemic off-target activity. Existing drugs and off-patent active
ingredients can be improved and re-patented as part of new formulations
using Marinosolv®. Under the brand Solv4U, Marinomed provides Marinosolv®
formulation development in technology partnerships for active ingredients
at all stages of drug discovery and for lifecycle extension. For more
information on Marinosolv® or Solv4U, please visit
(2)https://www.solv4u.com. Scientific publications on Marinosolv® can be
accessed in the “Immunology” tabs at
(3)https://www.marinomed.com/en/news/scientific-publications.
About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian, science-based biotech company with a
growing development pipeline and globally marketed therapeutics. The
Company develops innovative patent-protected products in the therapeutic
areas immunology and virology based on the platform Marinosolv® and the
virus-blocking activity of Carragelose®. The Marinosolv® technology
improves the solubility and bioavailability of hardly soluble compounds
and is used to develop new therapeutics for autoreactive immune disorders.
The virology segment includes Carragelose®-based over-the-counter (OTC)
products to prevent and treat respiratory viral infections that are
partnered in more than 40 countries. The Company is headquartered in
Korneuburg, Austria, and is listed on the Vienna Stock Exchange
(VSE:MARI). For further information, please visit:
(4)https://www.marinomed.com.
For further inquiries contact:
Marinomed Biotech AG
PR & IR: Lucia Ziegler
T: +43 2262 90300 158
E-Mail: (5)pr@marinomed.com
E-Mail: (6)ir@marinomed.com
Disclaimer
This press release contains forward-looking statements, which are based on
current views, expectations and projections of the management of Marinomed
Biotech AG about future events. These forward-looking statements are
subject to risks, uncertainties and assumptions that could cause actual
results, performance or events to differ materially from those described
in, or expressed or implied by, such statements. The current views,
expectations and projections of the management of Marinomed Biotech AG may
be identified by the context of such statements or words such as
“anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
and “target”. Forward-looking statements are only valid as of the date
they are made and Marinomed Biotech AG does not assume any obligation to
update, review or revise any forward-looking statements contained in this
press release whether as a result of new information, future developments
or otherwise. Marinomed, Marinosolv® and Carragelose® are registered
trademarks of Marinomed Biotech AG. These trademarks may be owned or
licensed in select locations only.
══════════════════════════════════════════════════════════════════════════
08.10.2024 CET/CEST This Corporate News was distributed by EQS Group AG.
www.eqs.com
══════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 2003579
End of News EQS News Service
2003579 08.10.2024 CET/CEST
References
Visible links
1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=0fecedee8150f3f0a4149cc07854b4d7&application_id=2003579&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
2. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=bd2eeb8ec4c89acd0f1d74110ad9cc92&application_id=2003579&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
3. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=22703f0463e8f6df4d84a973309eef6c&application_id=2003579&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b364e041c58da1aeff9758a10a9b0152&application_id=2003579&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
5. mailto:pr@marinomed.com
6. mailto:ir@marinomed.com
